Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: People with HIV (PWH) are at elevated risk of atherosclerotic cardiovascular disease (ASCVD), and current risk prediction tools underestimate risk among PWH. The American Heart Association developed new risk prediction equations, Predicting Risk of cardiovascular disease EVENTs (PREVENT), which have not been studied among PWH.

Objective: To compare predicted 10-year ASCVD risk using PREVENT with the pooled cohort equations (PCE) and the implications for statin recommendations among PWH.

Design: A cross-sectional observational study using real-world, electronic health records PARTICIPANTS: All people with HIV ages 40 to 75 without cardiovascular disease at 23 primary care and HIV clinics affiliated with two health systems in San Francisco, California from 2019 to 2024 MAIN MEASURES: We compared predicted 10-year ASCVD using the PREVENT equations and the PCE. Then we considered implications of PREVENT for statin therapy using current guidelines.

Key Results: Among 3357 PWH (median 57 years old; 73% male,12% female, 15% transgender/nonbinary/nondisclosed; 20% Black and 25% Latino), 91% were on antiretroviral therapy and 86% had virologic suppression. Among 2853 PWH with complete data for both calculators, the median predicted risk was 7.7% (interquartile range (IQR) 3.7, 14.0) using the PCE and 3.3% (IQR 1.9, 5.4) using PREVENT. Predicted risk was lower for 97% of individuals using PREVENT. Using a 10-year ASCVD risk threshold of 5%, only 28.6% of PWH would be strongly recommended for statins with PREVENT compared to 67.3% with PCE. The difference in predicted risk between the two equations varied across sex and race/ethnicity.

Conclusions: The PREVENT equations predict lower 10-year ASVCD risk for PWH compared to the PCE, which underpredicts risk for PWH. Underprediction of ASCVD risk, which -using new guidelines -would translate to 58% fewer PWH strongly recommended for statins using PREVENT compared to PCE, has the potential to increase cardiovascular disease and worsen healthcare disparities among PWH.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11606-025-09642-zDOI Listing

Publication Analysis

Top Keywords

cardiovascular disease
16
risk
14
people hiv
12
prevent equations
12
risk pwh
12
10-year ascvd
12
ascvd risk
12
predicted risk
12
prevent
10
pwh
9

Similar Publications

Pomegranate (Punica granatum L) is a rich source of bioactive compounds, including punicalagin, ellagic acid, anthocyanins, and urolithins, which contribute to its broad pharmacological potential. This review summarizes evidence from in vitro and in vivo experiments, as well as clinical studies, highlighting pomegranate's therapeutic effects in inflammation, metabolic disorders, cancer, cardiovascular disease, neurodegeneration, microbial infections, and skin conditions. Mechanistic insights show modulation of pathways such as nuclear factor-kappa B (NF-κB), mitogen-activated protein kinase (MAPK), alpha serine/threonine-protein kinase (AKT1), and nuclear factor erythroid 2-related factor 2 (Nrf2).

View Article and Find Full Text PDF

Bioactive Coatings for Cardiovascular Stents: Modulating Immune Response for Enhanced Performance.

ACS Biomater Sci Eng

September 2025

University Center for Research & Development (UCRD), Chandigarh University, NH-05 Chandigarh-Ludhiana Highway, Mohali 140413, Punjab, India.

Cardiovascular disorders remain a leading cause of death worldwide, and the use of contemporary stents is paving the way for a profound shift in the field of cardiology. In the surgical process postimplantation, the graft or stent and host-immune interaction play a significant role in the healing process, thus it is a major challenge in healthcare. To address these challenges, recent advancements have introduced bioactive coatings with specialized modifications in stents to enhance their interaction with surrounding environment.

View Article and Find Full Text PDF

Background: In-hospital cardiac arrest (IHCA) remains a public health conundrum with high morbidity and mortality rates. While early identification of high-risk patients could enable preventive interventions and improve survival, evidence on the effectiveness of current prediction methods remains inconclusive. Limited research exists on patients' prearrest pathophysiological status and predictive and prognostic factors of IHCA, highlighting the need for a comprehensive synthesis of predictive methodologies.

View Article and Find Full Text PDF

Fetal 4D Flow CMR for Advanced Diagnostics of Congenital Heart Disease: A Prospective Cohort Study.

Eur Heart J Cardiovasc Imaging

September 2025

Department of Diagnostic and Interventional Radiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.

Aims: Fetal circulation undergoes complex changes in congenital heart disease (CHD) that are challenging to assess with fetal echocardiography. This study aimed to assess clinical feasibility and diagnostic value of 4D flow cardiac magnetic resonance (CMR) in fetal CHD.

Methods And Results: Pregnant women in advanced third trimester pregnancy with fetal CHD were prospectively recruited for fetal CMR between 08/2021 and 11/2024.

View Article and Find Full Text PDF